CRNX News and Press, Crinetics Pharmaceuticals Inc. From 08/28/23

2023-08-28 18:07:28 ET Summary Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current...

2023-08-17 03:43:57 ET Summary Crinetics Pharmaceuticals has shown a significant increase in R&D and administrative expenses, leading to a widening net loss trajectory. The company's primary revenue source is the drug paltusotine, which has shown promising results in the treat...

2023-08-08 08:00:55 ET Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q2 GAAP EPS of -$0.94. Revenue of $1M (+150.0% Y/Y). For further details see: Crinetics Pharmaceuticals GAAP EPS of -$0.94, revenue of $1M

Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 CRN04777 Development Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET ...

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N.,...

Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics' Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from ENDO President SAN DIEGO, June 21, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmac...

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago...

2023-06-07 07:00:00 ET Summary High-yield dividend stocks are appealing, but they carry high amounts of risk. I demonstrate multiple examples. We present our new strategy to achieve high yields and 76 trades to snipe at market open. Written by Sam Kovacs Intr...

2023-05-25 12:25:15 ET Summary Crinetics Pharmaceuticals, Inc. is developing an oral nonpeptide drug for acromegaly patients. The drug is claimed to have advantages over injectable and oral somatostatin analogues. A phase 3 trial will establish that claim more strongly. ...

2023-05-04 17:31:44 ET Crinetics Pharmaceuticals press release ( NASDAQ: CRNX ): Q1 GAAP EPS of -$0.85 misses by $0.01 . Revenue of $2.67M (-14.7% Y/Y) beats by $2.43M . For further details see: Crinetics Pharmaceuticals GAAP EPS of -$0.85 misses by $0.01...